Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review.
Shivam Patel, Akash Gandhi, Arman Pabani et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review synthesized prospective interventional studies of pharmacologic therapies in adults with nonobstructive hypertrophic cardiomyopathy (HCM). It identified 29 trials across 9 drug classes; the abstract does not report a pooled effect estimate. Cardiac myosin inhibitors were associated with reduced left ventricular hypertrophy, improved diastolic function, and lower cardiac biomarkers, but effects on exercise capacity and symptoms varied. SGLT2 inhibitors showed improvements across several measures in symptomatic patients with comorbid type 2 diabetes. Overall, responses varied by treatment mechanism and disease stage.
Key findings
- The review identified 29 clinical trials evaluating 9 pharmacologic classes in adults with nonobstructive HCM.
- Cardiac myosin inhibitors reduced left ventricular hypertrophy and cardiac biomarkers and improved diastolic function; exercise and symptom benefits were variable.
- SGLT2 inhibition showed improvements in diastolic function, atrial remodeling, biomarkers, and functional status in symptomatic patients with type 2 diabetes.
- Valsartan and candesartan showed signals of structural remodeling without consistent functional benefit; mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibition were largely neutral.
Why it matters
Nonobstructive HCM has substantial morbidity, but the review found no consistent pharmacologic response across therapies or outcomes. The findings distinguish promising signals in selected treatment classes and patient groups from neutral or inconsistent results, while underscoring that changes in cardiac structure or biomarkers do not necessarily translate into better symptoms or exercise capacity.
What to keep in mind
The review used narrative synthesis across randomized and nonrandomized prospective trials, and the abstract provides no pooled effect estimates. Findings therefore span different drug classes and outcome domains.